Cost-effectiveness of lenalidomide in multiple myeloma

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 3, 2010, Pages 229-238

  Schey, Steve ^a   Higginson, Irene ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

discrete choice experiments; incremental cost effectiveness ratio; lenalidomide; quality adjusted life year

Indexed keywords

BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; PLACEBO; POMALIDOMIDE; PREDNISOLONE; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DNA MODIFICATION; DRUG ABSORPTION; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; IMMUNOMODULATION; LETHARGY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SINGLE DRUG DOSE; TERATOGENICITY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; ECONOMICS; STATISTICAL MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; MODELS, ECONOMIC; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 77953705837     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.19     Document Type: Review

References (65)

1. Drayson MT, Augustson BM, Begum G et al. Survival from relapse and the influence of therapy. XIth International Myeloma Workshop Proceedings. Haematologica 92(6 Suppl. 2), 173 (2007) (Abstract PO-665).
2. Vacca A, Ribatti D, Presta M et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93(9), 3064-3073 (1999).
3. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91(9), 4082-4085 (1994).
4. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565-1571 (1999).
5. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood 98(2), 492-494 (2001).
6. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum Phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk. Res. 27(10), 909-914 (2003).
7. Glasmacher A, Hahn C, Hoffmann F et al. A systematic review of Phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 132(5), 584-593 (2006).
8. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20(21), 4319-4323 (2002).
9. Rajkumar SV, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 17(4), 775-779 (2003).
10. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21(1), 16-19 (2003).
11. Gay F, Hayman S, Lacy M et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115(7), 1343-1350 (2010).
12. Schey SA, Jones R, Streetly M. A Phase I study of a new immunomodulatory thalidomide analogue CC 4047 (Actimid) in patients with relapsed/refractory multiple myeloma. J. Clin. Oncol. 22(16), 3269-3276 (2004).
13. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br. J. Haematol. 141(1), 41-51 (2008).
14. Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008-5014 (2009).
15. Lioznov M, El-Cheikh J Jr, Hoffmann F et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant. 45(2), 349-353 (2009).
16. LeBlanc R, Hideshima T, Catley LP et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103(5), 1787-1790 (2004).
17. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 57(12), 1849-1859 (2008).
18. Song W, van der Vliet HJ, Tai YT et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin. Cancer Res. 14(21), 6955-6962 (2008).
19. Galustian C, Meyer B, Labarthe MC et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 58(7), 1033-1045 (2009).
20. Gupta D, Treon SP, Shima Y et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12), 1950-1961 (2001).
21. Dredge K, Marriott JB, Macdonald CD et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer 87(10), 1166-1172 (2002).
22. Lentzsch S, LeBlanc R, Podar K et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17(1), 41-44 (2003).
23. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J. Immunol. 163(1), 380-386 (1999).
24. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-a and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Immunol. 130(1), 75-84 (2002).
25. Schafer PH, Gandhi AK, Loveland MA et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol. Exp. Ther. 305(3), 1222-1232 (2003).
26. Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin. Biol. Ther. 4(12), 1963-1970 (2004).
27. Dredge K, Horsfall R, Robinson SP et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc. Res. 69(1-2), 56-63 (2005).
28. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 5(5), 582-585 (1999).
29. Payvandi F, Wu L, Haley M et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-a, IL-1b, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell. Immunol. 230(2), 81-88 (2004).
30. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 69(18), 7347-7356 (2009).
31. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9), 3063-3067 (2002).
32. Zangari MTG, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of Phase I study of lenalidomide for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood 98(775A), (2001) (Abstract 3226).
33. Richardson PG, Blood E, Mitsiades CS et al. A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10), 3458-3464 (2006).
34. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133-2142 (2007).
35. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123-2132 (2007).
36. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13), 4050-4053 (2005).
37. Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11(1), 29-37 (2010).
38. Morgan GJ, Schey SA, Wu P et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br. J. Haematol. 137(3), 268-269 (2007).
39. Knop S, Gerecke C, Liebisch P et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113(18), 4137-4143 (2009).
40. Baz R, Walker E, Karam MA et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann. Oncol. 17(12), 1766-1771 (2006).
41. Palumbo A, Falco P, Falcone A et al. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin. Lymphoma Myeloma 9(2), 145-150 (2009).
42. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115(4), 834-845 (2010).
43. Morgan GJ, Davies FE, Cavenagh JD, Jackson GH. Position statement on the use of bortezomib in multiple myeloma. Int. J. Lab. Hematol. 30(1), 1-10 (2008).
44. McCarthy DA, Macey MG, Streetly M, Schey SA, Brown KA. The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. Int. Immunopharmacol. 6(7), 1194-1203 (2006).
45. Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur. J. Cancer 42(15), 2433-2453 (2006).
46. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2), 414-423 (2008).
47. Normand C. Measuring outcomes in palliative care: limitations of QALYs and the road to PalYs. J. Pain Symptom Manage. 38(1), 27-31 (2009).
48. Higginson IJ, Foley KM. Palliative care: no longer a luxury but a necessity? J. Pain Symptom Manage. 38(1), 1-3 (2009).
49. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J. Pain Symptom Manage. 31(1), 58-69 (2006).
50. Higginson IJ, Costantini M. Dying with cancer, living well with advanced cancer. Eur. J. Cancer 44(10), 1414-1424 (2008).
51. Koffman J, Morgan M, Edmonds P, Speck P, Higginson IJ. "I know he controls cancer": the meanings of religion among Black Caribbean and White British patients with advanced cancer. Soc. Sci. Med. 67(5), 780-789 (2008).
52. Higginson IJ, Donaldson N. Relationship between three palliative care outcome scales. Health Qual. Life Outcomes 2, 68 (2004).
53. Gomes B, Higginson IJ. Where people die (1974-2030): past trends, future projections and implications for care. Palliat. Med. 22(1), 33-41 (2008).
54. McCrone P. Capturing the costs of end-of-life care: comparisons of multiple sclerosis, Parkinson's disease, and dementia. J. Pain Symptom Manage. 38(1), 62-67 (2009).
55. British National Formulary (BNF) (55th Edition). BMJ Group and RPS Publishing, London, UK (2009).
56. Bonkowski JJ, Vermeulen LC, Kolesar JM. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. J. Oncol. Pharm. Pract. DOI: 0: 1078155209351967v1 (2009) (Epub ahead of print).
57. Douglas HR, Normand CE, Higginson IJ, Goodwin DM. A new approach to eliciting patients' pfor palliative day care: the choice experiment method. J. Pain Symptom Manage. 29(5), 435-445 (2005).
58. Muhlbacher AC, Lincke HJ, Nubling M. Evaluating patients' pfor multiple myeloma therapy, a discretechoice- experiment. Psychosoc. Med. 5, Doc10 (2008).
59. Cocks K, Cohen D, Wisloff F et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur. J. Cancer 43(11), 1670-1678 (2007).
60. Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur. J. Haematol. 83(4), 279-289 (2009).
61. King MT, Fayers PM. Making quality-oflife results more meaningful for clinicians. Lancet 371(9614), 709-710 (2008).
62. Cook R. Introduction: multiple myeloma. J. Manag. Care Pharm. 14(7 Suppl.), 4-6 (2008).
63. Davies Higginson IJ. Better palliative care for older people world health organization (2004) www.euro.who.int/document/e82933.pdf
64. National Institute for Health and Clinical Excellence (NICE). NICE technology appraisal guidance 171. Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. London, July 2009 www.nice.org.uk/TA171
65. The NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma (Version 1.2010). National Comprehensive Cancer Network, Inc. 2009 www.NCCN.org